| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Magnetic Resonance Imaging | 98 | 2021 | 1212 | 10.560 |
Why?
|
| Magnetic Resonance Imaging, Cine | 47 | 2020 | 99 | 7.930 |
Why?
|
| Ventricular Function, Left | 46 | 2021 | 264 | 7.120 |
Why?
|
| Ventricular Dysfunction, Left | 37 | 2021 | 168 | 6.880 |
Why?
|
| Stroke Volume | 45 | 2021 | 417 | 6.290 |
Why?
|
| Dobutamine | 29 | 2018 | 54 | 5.780 |
Why?
|
| Anthracyclines | 13 | 2020 | 52 | 5.750 |
Why?
|
| Heart Ventricles | 32 | 2018 | 146 | 5.180 |
Why?
|
| Exercise Test | 32 | 2021 | 218 | 4.660 |
Why?
|
| Antineoplastic Agents | 15 | 2020 | 595 | 4.610 |
Why?
|
| Heart Diseases | 15 | 2021 | 114 | 4.510 |
Why?
|
| Cardiovascular Diseases | 31 | 2021 | 1159 | 4.170 |
Why?
|
| Heart Failure | 32 | 2021 | 728 | 4.050 |
Why?
|
| Myocardial Ischemia | 20 | 2018 | 98 | 4.050 |
Why?
|
| Neoplasms | 16 | 2020 | 763 | 3.940 |
Why?
|
| Antibiotics, Antineoplastic | 12 | 2019 | 69 | 3.710 |
Why?
|
| Myocardium | 25 | 2019 | 184 | 3.380 |
Why?
|
| Middle Aged | 136 | 2021 | 11840 | 2.880 |
Why?
|
| Predictive Value of Tests | 48 | 2019 | 880 | 2.640 |
Why?
|
| Aged | 125 | 2021 | 10250 | 2.630 |
Why?
|
| Humans | 202 | 2021 | 32273 | 2.550 |
Why?
|
| Myocardial Contraction | 12 | 2016 | 59 | 2.360 |
Why?
|
| Male | 145 | 2021 | 19438 | 2.290 |
Why?
|
| Exercise Tolerance | 11 | 2021 | 119 | 2.290 |
Why?
|
| Female | 145 | 2021 | 19945 | 2.280 |
Why?
|
| Atherosclerosis | 31 | 2017 | 821 | 2.190 |
Why?
|
| Cardiotonic Agents | 12 | 2015 | 41 | 2.150 |
Why?
|
| Risk Assessment | 33 | 2021 | 1423 | 2.030 |
Why?
|
| Aorta, Thoracic | 13 | 2019 | 81 | 1.890 |
Why?
|
| Prognosis | 37 | 2018 | 1529 | 1.850 |
Why?
|
| Doxorubicin | 8 | 2019 | 75 | 1.790 |
Why?
|
| Myocardial Infarction | 16 | 2018 | 466 | 1.790 |
Why?
|
| Magnetic Resonance Angiography | 14 | 2015 | 72 | 1.790 |
Why?
|
| Aged, 80 and over | 64 | 2020 | 3893 | 1.770 |
Why?
|
| Risk Factors | 43 | 2020 | 3933 | 1.760 |
Why?
|
| Coronary Artery Disease | 16 | 2018 | 427 | 1.730 |
Why?
|
| Hypertrophy, Left Ventricular | 11 | 2019 | 122 | 1.700 |
Why?
|
| Contrast Media | 16 | 2015 | 136 | 1.680 |
Why?
|
| Ventricular Remodeling | 12 | 2019 | 63 | 1.680 |
Why?
|
| Coronary Circulation | 14 | 2016 | 41 | 1.680 |
Why?
|
| Myocardial Perfusion Imaging | 4 | 2016 | 24 | 1.640 |
Why?
|
| Time Factors | 27 | 2020 | 2203 | 1.640 |
Why?
|
| Chest Pain | 5 | 2019 | 205 | 1.610 |
Why?
|
| Diagnostic Imaging | 9 | 2015 | 89 | 1.560 |
Why?
|
| Prospective Studies | 40 | 2021 | 2316 | 1.540 |
Why?
|
| Emergency Service, Hospital | 5 | 2019 | 444 | 1.530 |
Why?
|
| Aortic Diseases | 8 | 2015 | 62 | 1.530 |
Why?
|
| Cardiomyopathies | 10 | 2018 | 67 | 1.490 |
Why?
|
| Aorta | 9 | 2015 | 125 | 1.460 |
Why?
|
| Ethnic Groups | 17 | 2017 | 450 | 1.360 |
Why?
|
| Coronary Vessels | 8 | 2017 | 174 | 1.340 |
Why?
|
| Breast Neoplasms | 7 | 2020 | 764 | 1.290 |
Why?
|
| Heart | 11 | 2019 | 177 | 1.220 |
Why?
|
| Adult | 50 | 2020 | 9261 | 1.220 |
Why?
|
| Cardiovascular System | 3 | 2018 | 49 | 1.180 |
Why?
|
| Cardiotoxins | 2 | 2018 | 9 | 1.090 |
Why?
|
| Cardiac Output | 4 | 2019 | 33 | 1.080 |
Why?
|
| Radiation Injuries | 3 | 2019 | 85 | 1.070 |
Why?
|
| Electrocardiography | 17 | 2021 | 624 | 0.990 |
Why?
|
| Cardiology | 6 | 2020 | 104 | 0.960 |
Why?
|
| Echocardiography, Stress | 6 | 2016 | 23 | 0.940 |
Why?
|
| Echocardiography | 14 | 2019 | 190 | 0.940 |
Why?
|
| Intra-Abdominal Fat | 5 | 2018 | 58 | 0.910 |
Why?
|
| Coronary Disease | 9 | 2015 | 226 | 0.890 |
Why?
|
| Hematologic Neoplasms | 2 | 2015 | 39 | 0.870 |
Why?
|
| Medical Oncology | 3 | 2020 | 90 | 0.860 |
Why?
|
| Aging | 9 | 2016 | 942 | 0.850 |
Why?
|
| Hypertension | 6 | 2021 | 980 | 0.840 |
Why?
|
| Fibrosis | 10 | 2021 | 126 | 0.840 |
Why?
|
| Acute Coronary Syndrome | 4 | 2019 | 167 | 0.830 |
Why?
|
| Ventricular Function, Right | 4 | 2013 | 17 | 0.800 |
Why?
|
| Mitral Valve Insufficiency | 4 | 2018 | 27 | 0.790 |
Why?
|
| Sex Factors | 9 | 2017 | 656 | 0.780 |
Why?
|
| Isolated Noncompaction of the Ventricular Myocardium | 4 | 2015 | 5 | 0.750 |
Why?
|
| Adipose Tissue | 4 | 2014 | 320 | 0.750 |
Why?
|
| Pulmonary Edema | 2 | 2014 | 12 | 0.750 |
Why?
|
| Heptanoic Acids | 2 | 2014 | 33 | 0.730 |
Why?
|
| Blood Flow Velocity | 8 | 2011 | 77 | 0.720 |
Why?
|
| Pyrroles | 2 | 2014 | 59 | 0.720 |
Why?
|
| Hemodynamics | 8 | 2015 | 164 | 0.720 |
Why?
|
| Age Factors | 14 | 2018 | 1178 | 0.710 |
Why?
|
| Organometallic Compounds | 3 | 2010 | 18 | 0.670 |
Why?
|
| Survivors | 3 | 2018 | 174 | 0.650 |
Why?
|
| Health Status Indicators | 1 | 2021 | 69 | 0.650 |
Why?
|
| Heart Neoplasms | 1 | 2020 | 19 | 0.650 |
Why?
|
| Cardiac Volume | 4 | 2017 | 13 | 0.650 |
Why?
|
| Coronary Stenosis | 3 | 2016 | 28 | 0.630 |
Why?
|
| Reproducibility of Results | 12 | 2017 | 756 | 0.620 |
Why?
|
| Vasodilator Agents | 4 | 2014 | 62 | 0.620 |
Why?
|
| United States | 32 | 2019 | 4069 | 0.610 |
Why?
|
| Coronary Angiography | 12 | 2015 | 159 | 0.600 |
Why?
|
| Oxygen Consumption | 11 | 2021 | 141 | 0.600 |
Why?
|
| Edema, Cardiac | 2 | 2016 | 12 | 0.600 |
Why?
|
| Pericardium | 4 | 2014 | 52 | 0.590 |
Why?
|
| Endothelium, Vascular | 6 | 2018 | 155 | 0.590 |
Why?
|
| Models, Cardiovascular | 6 | 2016 | 31 | 0.560 |
Why?
|
| Image Enhancement | 6 | 2015 | 66 | 0.550 |
Why?
|
| Linear Models | 12 | 2019 | 426 | 0.530 |
Why?
|
| Population Surveillance | 4 | 2017 | 120 | 0.530 |
Why?
|
| Arteries | 3 | 2009 | 75 | 0.530 |
Why?
|
| Obesity, Abdominal | 2 | 2015 | 24 | 0.520 |
Why?
|
| Collagen | 1 | 2018 | 229 | 0.520 |
Why?
|
| Adrenergic beta-Agonists | 3 | 2009 | 31 | 0.500 |
Why?
|
| Disease Progression | 6 | 2018 | 591 | 0.500 |
Why?
|
| Adiposity | 2 | 2016 | 190 | 0.500 |
Why?
|
| Gadolinium | 4 | 2015 | 18 | 0.490 |
Why?
|
| Case-Control Studies | 8 | 2021 | 854 | 0.490 |
Why?
|
| Prediabetic State | 2 | 2015 | 76 | 0.480 |
Why?
|
| Atropine | 8 | 2011 | 19 | 0.480 |
Why?
|
| Angina Pectoris | 3 | 2018 | 20 | 0.470 |
Why?
|
| Patient Positioning | 1 | 2015 | 21 | 0.460 |
Why?
|
| Follow-Up Studies | 13 | 2017 | 2238 | 0.460 |
Why?
|
| Stress, Physiological | 2 | 2016 | 57 | 0.460 |
Why?
|
| Abdominal Fat | 2 | 2018 | 39 | 0.460 |
Why?
|
| Bilirubin | 1 | 2015 | 23 | 0.460 |
Why?
|
| Severity of Illness Index | 11 | 2019 | 854 | 0.440 |
Why?
|
| North Carolina | 6 | 2015 | 1300 | 0.440 |
Why?
|
| Echocardiography, Doppler | 8 | 2021 | 44 | 0.440 |
Why?
|
| Incidence | 11 | 2018 | 1242 | 0.430 |
Why?
|
| Simvastatin | 1 | 2014 | 26 | 0.430 |
Why?
|
| Tubulin Modulators | 1 | 2014 | 9 | 0.430 |
Why?
|
| Proportional Hazards Models | 9 | 2017 | 772 | 0.430 |
Why?
|
| Subcutaneous Fat | 2 | 2015 | 43 | 0.430 |
Why?
|
| Observer Variation | 9 | 2017 | 96 | 0.420 |
Why?
|
| Continental Population Groups | 6 | 2017 | 228 | 0.420 |
Why?
|
| Prevalence | 10 | 2019 | 955 | 0.410 |
Why?
|
| Renal Circulation | 1 | 2014 | 12 | 0.410 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2014 | 11 | 0.410 |
Why?
|
| Furosemide | 1 | 2014 | 8 | 0.410 |
Why?
|
| Renal Artery Obstruction | 1 | 2014 | 38 | 0.410 |
Why?
|
| Renal Artery | 1 | 2014 | 47 | 0.400 |
Why?
|
| Ventricular Function | 4 | 2012 | 8 | 0.400 |
Why?
|
| Retrospective Studies | 12 | 2019 | 3609 | 0.400 |
Why?
|
| Blood Glucose | 3 | 2015 | 484 | 0.400 |
Why?
|
| Tomography, X-Ray Computed | 12 | 2015 | 904 | 0.400 |
Why?
|
| Cross-Sectional Studies | 10 | 2017 | 1480 | 0.390 |
Why?
|
| Multivariate Analysis | 8 | 2016 | 650 | 0.390 |
Why?
|
| Disability Evaluation | 1 | 2014 | 241 | 0.390 |
Why?
|
| Oxygen | 1 | 2014 | 138 | 0.390 |
Why?
|
| Cardiology Service, Hospital | 1 | 2013 | 19 | 0.390 |
Why?
|
| Cohort Studies | 18 | 2019 | 1840 | 0.380 |
Why?
|
| Leukemia | 1 | 2013 | 38 | 0.380 |
Why?
|
| Lymphoma | 1 | 2013 | 37 | 0.380 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 167 | 0.380 |
Why?
|
| Heterocyclic Compounds | 2 | 2010 | 14 | 0.380 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 245 | 0.380 |
Why?
|
| Heart Rate | 7 | 2017 | 364 | 0.370 |
Why?
|
| Hospitalization | 4 | 2020 | 475 | 0.370 |
Why?
|
| Diastole | 11 | 2021 | 98 | 0.370 |
Why?
|
| Image Processing, Computer-Assisted | 6 | 2016 | 232 | 0.350 |
Why?
|
| Atrial Function, Left | 1 | 2012 | 22 | 0.350 |
Why?
|
| Sensitivity and Specificity | 7 | 2014 | 556 | 0.350 |
Why?
|
| Obesity | 6 | 2021 | 1111 | 0.340 |
Why?
|
| Gadolinium DTPA | 3 | 2012 | 15 | 0.340 |
Why?
|
| Health Expenditures | 1 | 2011 | 66 | 0.340 |
Why?
|
| Hospital Costs | 1 | 2011 | 48 | 0.340 |
Why?
|
| Patient Admission | 1 | 2011 | 54 | 0.330 |
Why?
|
| Inpatients | 1 | 2011 | 83 | 0.330 |
Why?
|
| Angina, Unstable | 4 | 2015 | 13 | 0.320 |
Why?
|
| Reference Values | 11 | 2016 | 238 | 0.320 |
Why?
|
| Chi-Square Distribution | 5 | 2015 | 287 | 0.320 |
Why?
|
| Heart Function Tests | 3 | 2010 | 8 | 0.320 |
Why?
|
| Health Care Costs | 2 | 2010 | 122 | 0.320 |
Why?
|
| Societies, Medical | 7 | 2015 | 153 | 0.320 |
Why?
|
| Animals | 12 | 2019 | 8196 | 0.310 |
Why?
|
| Bicycling | 1 | 2009 | 12 | 0.310 |
Why?
|
| Delivery of Health Care | 1 | 2011 | 167 | 0.300 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2009 | 49 | 0.300 |
Why?
|
| Meglumine | 1 | 2009 | 3 | 0.300 |
Why?
|
| Fluorocarbons | 2 | 1999 | 21 | 0.300 |
Why?
|
| Image Interpretation, Computer-Assisted | 5 | 2017 | 103 | 0.300 |
Why?
|
| Femoral Artery | 3 | 2009 | 45 | 0.290 |
Why?
|
| Infusions, Intravenous | 6 | 2012 | 97 | 0.290 |
Why?
|
| Women's Health Services | 1 | 2009 | 10 | 0.290 |
Why?
|
| Systole | 10 | 2018 | 94 | 0.290 |
Why?
|
| Advisory Committees | 3 | 2015 | 35 | 0.290 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2010 | 157 | 0.290 |
Why?
|
| C-Reactive Protein | 5 | 2020 | 227 | 0.290 |
Why?
|
| Glucose Intolerance | 1 | 2009 | 40 | 0.290 |
Why?
|
| Medical Records | 1 | 2009 | 75 | 0.290 |
Why?
|
| Lower Extremity | 1 | 2009 | 99 | 0.280 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2010 | 216 | 0.280 |
Why?
|
| Longitudinal Studies | 6 | 2020 | 759 | 0.280 |
Why?
|
| Heart Valve Diseases | 2 | 2007 | 28 | 0.260 |
Why?
|
| Leg | 2 | 2006 | 67 | 0.250 |
Why?
|
| Regional Blood Flow | 3 | 2015 | 85 | 0.250 |
Why?
|
| Heart Defects, Congenital | 1 | 2007 | 34 | 0.250 |
Why?
|
| Kidney | 1 | 2010 | 521 | 0.250 |
Why?
|
| Vasodilation | 5 | 2013 | 92 | 0.240 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2003 | 71 | 0.240 |
Why?
|
| Radiotherapy | 2 | 2018 | 92 | 0.240 |
Why?
|
| Exercise | 3 | 2014 | 605 | 0.230 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2007 | 116 | 0.230 |
Why?
|
| Blood Pressure | 7 | 2013 | 864 | 0.230 |
Why?
|
| Troponin | 2 | 2019 | 101 | 0.230 |
Why?
|
| Heart Atria | 2 | 2010 | 81 | 0.230 |
Why?
|
| Myocytes, Cardiac | 3 | 2019 | 90 | 0.210 |
Why?
|
| Sex Characteristics | 4 | 2019 | 173 | 0.210 |
Why?
|
| Drug Administration Schedule | 3 | 2014 | 276 | 0.210 |
Why?
|
| Adenosine | 6 | 2011 | 68 | 0.200 |
Why?
|
| Carotid Artery Diseases | 2 | 2015 | 126 | 0.200 |
Why?
|
| Calcinosis | 2 | 2010 | 142 | 0.190 |
Why?
|
| European Continental Ancestry Group | 6 | 2017 | 1076 | 0.190 |
Why?
|
| Aneurysm, False | 1 | 2003 | 15 | 0.190 |
Why?
|
| Ventricular Dysfunction, Right | 2 | 2015 | 19 | 0.190 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2020 | 185 | 0.180 |
Why?
|
| Algorithms | 4 | 2017 | 536 | 0.180 |
Why?
|
| Natriuretic Peptide, Brain | 4 | 2020 | 86 | 0.180 |
Why?
|
| Intraoperative Complications | 1 | 2002 | 55 | 0.180 |
Why?
|
| Smoking | 3 | 2015 | 505 | 0.180 |
Why?
|
| Early Diagnosis | 2 | 2013 | 57 | 0.180 |
Why?
|
| Cardiac-Gated Imaging Techniques | 4 | 2019 | 18 | 0.180 |
Why?
|
| Peptide Fragments | 3 | 2020 | 415 | 0.170 |
Why?
|
| Inflammation | 2 | 2015 | 507 | 0.170 |
Why?
|
| African Americans | 5 | 2020 | 1335 | 0.170 |
Why?
|
| American Heart Association | 5 | 2014 | 92 | 0.170 |
Why?
|
| Length of Stay | 2 | 2013 | 321 | 0.170 |
Why?
|
| Feasibility Studies | 2 | 2017 | 309 | 0.170 |
Why?
|
| Analysis of Variance | 4 | 2016 | 471 | 0.170 |
Why?
|
| Comorbidity | 2 | 2016 | 563 | 0.160 |
Why?
|
| Diagnosis, Differential | 2 | 2019 | 501 | 0.160 |
Why?
|
| Radiography | 5 | 2010 | 358 | 0.160 |
Why?
|
| Muscle, Skeletal | 2 | 2018 | 520 | 0.160 |
Why?
|
| Rats | 3 | 2018 | 1895 | 0.160 |
Why?
|
| Receptor, erbB-2 | 1 | 2020 | 63 | 0.150 |
Why?
|
| Pulmonary Artery | 2 | 1999 | 26 | 0.150 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2019 | 5 | 0.150 |
Why?
|
| Body Mass Index | 5 | 2015 | 863 | 0.150 |
Why?
|
| Atrial Fibrillation | 2 | 2010 | 410 | 0.150 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 2 | 2009 | 14 | 0.150 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2019 | 38 | 0.140 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2019 | 56 | 0.140 |
Why?
|
| Muscle Proteins | 1 | 2019 | 63 | 0.140 |
Why?
|
| Rats, Inbred SHR | 1 | 2018 | 35 | 0.140 |
Why?
|
| Receptors, Neurokinin-1 | 1 | 2018 | 5 | 0.140 |
Why?
|
| Muscular Atrophy | 1 | 2019 | 74 | 0.140 |
Why?
|
| Rats, Wistar | 1 | 2018 | 111 | 0.140 |
Why?
|
| Atrophy | 1 | 2018 | 46 | 0.140 |
Why?
|
| Ultrasonography | 8 | 2013 | 393 | 0.140 |
Why?
|
| Body Fat Distribution | 1 | 2018 | 25 | 0.140 |
Why?
|
| Procollagen | 1 | 2018 | 7 | 0.140 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2018 | 8 | 0.140 |
Why?
|
| Fibroblasts | 1 | 2018 | 119 | 0.130 |
Why?
|
| Random Allocation | 1 | 2018 | 247 | 0.130 |
Why?
|
| Models, Animal | 1 | 2018 | 188 | 0.130 |
Why?
|
| Collagen Type I | 1 | 2018 | 44 | 0.130 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2018 | 93 | 0.130 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2020 | 211 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 4 | 2014 | 395 | 0.130 |
Why?
|
| Mitral Valve | 1 | 2018 | 33 | 0.130 |
Why?
|
| Microcirculation | 2 | 2016 | 66 | 0.130 |
Why?
|
| Injections, Intraperitoneal | 2 | 2019 | 45 | 0.130 |
Why?
|
| Pain Measurement | 1 | 2019 | 339 | 0.130 |
Why?
|
| Myocardial Revascularization | 2 | 2013 | 34 | 0.130 |
Why?
|
| Automation | 1 | 2017 | 28 | 0.130 |
Why?
|
| Heart Failure, Diastolic | 1 | 2017 | 15 | 0.130 |
Why?
|
| African Continental Ancestry Group | 2 | 2017 | 338 | 0.130 |
Why?
|
| Stress, Mechanical | 1 | 2017 | 96 | 0.130 |
Why?
|
| Spironolactone | 1 | 2017 | 11 | 0.130 |
Why?
|
| Peptides | 1 | 2018 | 127 | 0.130 |
Why?
|
| Lysine | 1 | 2017 | 23 | 0.130 |
Why?
|
| Brachial Artery | 2 | 2014 | 72 | 0.120 |
Why?
|
| Least-Squares Analysis | 1 | 2016 | 32 | 0.120 |
Why?
|
| Subcutaneous Fat, Abdominal | 2 | 2018 | 12 | 0.120 |
Why?
|
| Atrial Function | 2 | 2010 | 3 | 0.120 |
Why?
|
| Diet, Mediterranean | 1 | 2016 | 31 | 0.120 |
Why?
|
| Statistics as Topic | 2 | 2009 | 99 | 0.120 |
Why?
|
| Double-Blind Method | 3 | 2017 | 566 | 0.120 |
Why?
|
| Aorta, Abdominal | 2 | 2014 | 31 | 0.120 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 422 | 0.120 |
Why?
|
| Idarubicin | 1 | 2015 | 8 | 0.120 |
Why?
|
| Survival Rate | 2 | 2017 | 892 | 0.120 |
Why?
|
| Daunorubicin | 1 | 2015 | 27 | 0.120 |
Why?
|
| Disease Models, Animal | 3 | 2019 | 1081 | 0.110 |
Why?
|
| Aortography | 1 | 2015 | 16 | 0.110 |
Why?
|
| Weight Loss | 1 | 2018 | 410 | 0.110 |
Why?
|
| Quality of Life | 5 | 2013 | 969 | 0.110 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2018 | 897 | 0.110 |
Why?
|
| Patient Compliance | 1 | 2016 | 206 | 0.110 |
Why?
|
| Papillary Muscles | 1 | 2014 | 2 | 0.110 |
Why?
|
| Carotid Arteries | 3 | 2013 | 109 | 0.110 |
Why?
|
| Calcium | 1 | 1996 | 339 | 0.110 |
Why?
|
| Organ Size | 5 | 2016 | 221 | 0.110 |
Why?
|
| Disease-Free Survival | 3 | 2015 | 322 | 0.110 |
Why?
|
| Genetic Testing | 1 | 2015 | 90 | 0.110 |
Why?
|
| Cerebrovascular Disorders | 1 | 2015 | 51 | 0.110 |
Why?
|
| Extracellular Matrix | 1 | 2016 | 256 | 0.110 |
Why?
|
| Mass Screening | 1 | 1996 | 256 | 0.110 |
Why?
|
| Radiation Dosage | 3 | 2010 | 90 | 0.110 |
Why?
|
| Body Surface Area | 2 | 2014 | 15 | 0.110 |
Why?
|
| Treatment Outcome | 4 | 2014 | 3408 | 0.100 |
Why?
|
| Disease Management | 1 | 2015 | 129 | 0.100 |
Why?
|
| Oxidative Stress | 1 | 2015 | 255 | 0.100 |
Why?
|
| Fibrinogen | 1 | 2013 | 65 | 0.100 |
Why?
|
| Administration, Oral | 1 | 2014 | 200 | 0.100 |
Why?
|
| Observation | 1 | 2013 | 22 | 0.100 |
Why?
|
| Troponin I | 1 | 2013 | 20 | 0.100 |
Why?
|
| Activities of Daily Living | 1 | 2014 | 246 | 0.100 |
Why?
|
| Data Collection | 2 | 2015 | 171 | 0.100 |
Why?
|
| Clinical Competence | 4 | 2015 | 329 | 0.090 |
Why?
|
| Heart Failure, Systolic | 1 | 2012 | 15 | 0.090 |
Why?
|
| Mobility Limitation | 1 | 2014 | 208 | 0.090 |
Why?
|
| Interleukin-6 | 1 | 2013 | 224 | 0.090 |
Why?
|
| Smoking Cessation | 1 | 2015 | 211 | 0.090 |
Why?
|
| Hispanic Americans | 5 | 2009 | 772 | 0.090 |
Why?
|
| Phantoms, Imaging | 2 | 2010 | 70 | 0.090 |
Why?
|
| Patient Readmission | 1 | 2013 | 135 | 0.090 |
Why?
|
| Body Composition | 2 | 2010 | 327 | 0.090 |
Why?
|
| Radionuclide Imaging | 1 | 2011 | 26 | 0.090 |
Why?
|
| Serotonin Uptake Inhibitors | 1 | 2012 | 41 | 0.090 |
Why?
|
| Models, Economic | 1 | 2011 | 18 | 0.090 |
Why?
|
| Cost Savings | 1 | 2011 | 34 | 0.090 |
Why?
|
| Elasticity | 3 | 2013 | 41 | 0.090 |
Why?
|
| Drug Costs | 1 | 2011 | 46 | 0.080 |
Why?
|
| Recurrence | 2 | 2003 | 286 | 0.080 |
Why?
|
| Exercise Therapy | 1 | 2013 | 249 | 0.080 |
Why?
|
| Ventricular Pressure | 2 | 2021 | 5 | 0.080 |
Why?
|
| Thigh | 2 | 2018 | 35 | 0.080 |
Why?
|
| Radiopharmaceuticals | 1 | 2011 | 95 | 0.080 |
Why?
|
| Acute Disease | 1 | 2011 | 253 | 0.080 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2010 | 10 | 0.080 |
Why?
|
| History, 21st Century | 1 | 2010 | 62 | 0.080 |
Why?
|
| Pulsatile Flow | 1 | 2010 | 19 | 0.080 |
Why?
|
| History, 20th Century | 1 | 2010 | 74 | 0.080 |
Why?
|
| Enalapril | 1 | 2010 | 8 | 0.080 |
Why?
|
| Foundations | 1 | 2010 | 8 | 0.080 |
Why?
|
| Periodicals as Topic | 1 | 2011 | 90 | 0.080 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2010 | 14 | 0.080 |
Why?
|
| Sex Distribution | 3 | 2016 | 174 | 0.080 |
Why?
|
| Patient Discharge | 1 | 2011 | 204 | 0.080 |
Why?
|
| Medroxyprogesterone | 1 | 2010 | 13 | 0.080 |
Why?
|
| Intention to Treat Analysis | 1 | 2010 | 25 | 0.080 |
Why?
|
| Age Distribution | 3 | 2016 | 194 | 0.080 |
Why?
|
| Costs and Cost Analysis | 1 | 2010 | 106 | 0.080 |
Why?
|
| Body Height | 1 | 2010 | 34 | 0.080 |
Why?
|
| Carotid Artery, Common | 1 | 2010 | 48 | 0.080 |
Why?
|
| Anthropometry | 1 | 2010 | 89 | 0.080 |
Why?
|
| Adolescent | 4 | 2001 | 3516 | 0.080 |
Why?
|
| Tissue Survival | 1 | 2009 | 13 | 0.080 |
Why?
|
| Iliac Artery | 1 | 2009 | 50 | 0.080 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 133 | 0.080 |
Why?
|
| Young Adult | 2 | 2013 | 2651 | 0.070 |
Why?
|
| Computer Simulation | 1 | 2010 | 251 | 0.070 |
Why?
|
| Catheter Ablation | 1 | 2010 | 113 | 0.070 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2008 | 3 | 0.070 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 292 | 0.070 |
Why?
|
| Single-Blind Method | 2 | 2013 | 192 | 0.070 |
Why?
|
| Muscle Contraction | 1 | 2009 | 175 | 0.070 |
Why?
|
| Capillaries | 1 | 2008 | 25 | 0.070 |
Why?
|
| Quality Assurance, Health Care | 1 | 2009 | 72 | 0.070 |
Why?
|
| Quadriceps Muscle | 1 | 2008 | 29 | 0.070 |
Why?
|
| Odds Ratio | 2 | 2015 | 455 | 0.070 |
Why?
|
| Diabetes Complications | 2 | 2006 | 171 | 0.070 |
Why?
|
| Health Policy | 1 | 2008 | 89 | 0.070 |
Why?
|
| Body Weight | 1 | 2010 | 323 | 0.070 |
Why?
|
| Patient Selection | 3 | 2010 | 272 | 0.070 |
Why?
|
| Vasomotor System | 1 | 1988 | 25 | 0.070 |
Why?
|
| Up-Regulation | 2 | 2019 | 193 | 0.070 |
Why?
|
| Postmenopause | 1 | 2010 | 424 | 0.070 |
Why?
|
| Antihypertensive Agents | 1 | 2010 | 363 | 0.070 |
Why?
|
| Cerebrovascular Circulation | 1 | 1988 | 92 | 0.060 |
Why?
|
| Transplants | 1 | 2007 | 22 | 0.060 |
Why?
|
| Tachycardia, Ventricular | 1 | 2006 | 26 | 0.060 |
Why?
|
| Rest | 1 | 2006 | 49 | 0.060 |
Why?
|
| Death | 1 | 2006 | 51 | 0.060 |
Why?
|
| Ischemia | 1 | 2006 | 115 | 0.060 |
Why?
|
| Medical Staff Privileges | 1 | 2005 | 2 | 0.060 |
Why?
|
| Risk | 1 | 2006 | 305 | 0.060 |
Why?
|
| Thiazoles | 1 | 2005 | 36 | 0.050 |
Why?
|
| Torsion, Mechanical | 2 | 2016 | 6 | 0.050 |
Why?
|
| Vascular Resistance | 1 | 2004 | 32 | 0.050 |
Why?
|
| Inflammation Mediators | 2 | 2015 | 96 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2016 | 476 | 0.050 |
Why?
|
| Arteriosclerosis | 1 | 2004 | 147 | 0.050 |
Why?
|
| Asian Americans | 3 | 2009 | 92 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2019 | 716 | 0.050 |
Why?
|
| Angiography | 2 | 2013 | 76 | 0.050 |
Why?
|
| Diabetic Angiopathies | 1 | 2004 | 150 | 0.050 |
Why?
|
| Respiration | 3 | 1996 | 29 | 0.040 |
Why?
|
| Stimulation, Chemical | 1 | 2001 | 16 | 0.040 |
Why?
|
| Diabetes Mellitus | 1 | 2004 | 390 | 0.040 |
Why?
|
| Mississippi | 1 | 2020 | 38 | 0.040 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2000 | 5 | 0.040 |
Why?
|
| Cell Size | 1 | 2019 | 40 | 0.040 |
Why?
|
| Radiotherapy Dosage | 1 | 2019 | 106 | 0.040 |
Why?
|
| Arteriovenous Malformations | 1 | 1999 | 7 | 0.040 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2000 | 52 | 0.040 |
Why?
|
| Pulmonary Veins | 1 | 1999 | 20 | 0.040 |
Why?
|
| Troponin T | 1 | 2020 | 92 | 0.040 |
Why?
|
| Polysomnography | 1 | 2019 | 39 | 0.040 |
Why?
|
| Echocardiography, Transesophageal | 2 | 1999 | 58 | 0.040 |
Why?
|
| Independent Living | 1 | 2019 | 90 | 0.040 |
Why?
|
| Hematopoiesis | 1 | 2018 | 29 | 0.030 |
Why?
|
| Absorptiometry, Photon | 1 | 2018 | 98 | 0.030 |
Why?
|
| Compliance | 2 | 2010 | 14 | 0.030 |
Why?
|
| Cell Survival | 1 | 2018 | 286 | 0.030 |
Why?
|
| Gene Expression | 1 | 2019 | 346 | 0.030 |
Why?
|
| Consensus | 1 | 2018 | 87 | 0.030 |
Why?
|
| Muscle Strength | 1 | 2018 | 135 | 0.030 |
Why?
|
| Registries | 2 | 2009 | 294 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 191 | 0.030 |
Why?
|
| Texas | 1 | 2017 | 41 | 0.030 |
Why?
|
| Radionuclide Ventriculography | 1 | 1996 | 1 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2017 | 132 | 0.030 |
Why?
|
| Apoptosis | 1 | 2018 | 375 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 792 | 0.030 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 1996 | 34 | 0.030 |
Why?
|
| Discriminant Analysis | 1 | 2015 | 20 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2015 | 67 | 0.030 |
Why?
|
| Indicator Dilution Techniques | 1 | 1995 | 1 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 551 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2015 | 82 | 0.030 |
Why?
|
| Oximetry | 1 | 1995 | 32 | 0.030 |
Why?
|
| Blood Pressure Determination | 1 | 2016 | 106 | 0.030 |
Why?
|
| Adipokines | 1 | 2015 | 11 | 0.030 |
Why?
|
| Cause of Death | 1 | 2016 | 236 | 0.030 |
Why?
|
| Vascular Patency | 1 | 1995 | 66 | 0.030 |
Why?
|
| Cotinine | 1 | 2015 | 40 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2015 | 187 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2014 | 141 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2015 | 117 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2014 | 273 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 130 | 0.030 |
Why?
|
| Medicare | 1 | 1995 | 218 | 0.030 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2013 | 14 | 0.030 |
Why?
|
| Mice | 1 | 2019 | 2571 | 0.020 |
Why?
|
| Logistic Models | 1 | 2015 | 743 | 0.020 |
Why?
|
| Health Surveys | 1 | 2013 | 175 | 0.020 |
Why?
|
| Dilatation, Pathologic | 1 | 2012 | 20 | 0.020 |
Why?
|
| Decision Making | 1 | 2014 | 190 | 0.020 |
Why?
|
| Perfusion | 1 | 2011 | 75 | 0.020 |
Why?
|
| Journal Impact Factor | 1 | 2011 | 11 | 0.020 |
Why?
|
| Peer Review, Research | 1 | 2011 | 11 | 0.020 |
Why?
|
| Editorial Policies | 1 | 2011 | 14 | 0.020 |
Why?
|
| Europe | 1 | 2010 | 82 | 0.020 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2010 | 8 | 0.020 |
Why?
|
| Unnecessary Procedures | 1 | 2010 | 16 | 0.020 |
Why?
|
| Software | 1 | 2011 | 124 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2010 | 83 | 0.020 |
Why?
|
| Probability | 1 | 2010 | 155 | 0.020 |
Why?
|
| Elastic Modulus | 1 | 2010 | 29 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2010 | 95 | 0.020 |
Why?
|
| Waist Circumference | 1 | 2010 | 91 | 0.020 |
Why?
|
| Fasting | 1 | 2009 | 88 | 0.020 |
Why?
|
| Accreditation | 1 | 2009 | 16 | 0.020 |
Why?
|
| Triglycerides | 1 | 2009 | 235 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2009 | 83 | 0.020 |
Why?
|
| Geriatric Assessment | 1 | 2010 | 335 | 0.020 |
Why?
|
| Verapamil | 1 | 1988 | 8 | 0.020 |
Why?
|
| Arterioles | 1 | 1988 | 16 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2009 | 161 | 0.020 |
Why?
|
| Wakefulness | 1 | 1988 | 25 | 0.020 |
Why?
|
| Acetylcholine | 1 | 1988 | 69 | 0.020 |
Why?
|
| Rabbits | 1 | 1988 | 217 | 0.020 |
Why?
|
| Homeostasis | 1 | 1988 | 130 | 0.020 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2006 | 101 | 0.010 |
Why?
|
| Dogs | 2 | 1996 | 125 | 0.010 |
Why?
|
| Credentialing | 1 | 2005 | 7 | 0.010 |
Why?
|
| Models, Biological | 1 | 2007 | 408 | 0.010 |
Why?
|
| Education, Medical, Continuing | 1 | 2005 | 49 | 0.010 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2005 | 20 | 0.010 |
Why?
|
| Plethysmography | 1 | 2004 | 18 | 0.010 |
Why?
|
| ROC Curve | 1 | 2004 | 169 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2005 | 137 | 0.010 |
Why?
|
| Ergometry | 1 | 2002 | 4 | 0.010 |
Why?
|
| Natriuretic Agents | 1 | 2002 | 3 | 0.010 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2002 | 10 | 0.010 |
Why?
|
| Catecholamines | 1 | 2002 | 17 | 0.010 |
Why?
|
| Physical Endurance | 1 | 2002 | 40 | 0.010 |
Why?
|
| Diabetic Nephropathies | 1 | 2004 | 223 | 0.010 |
Why?
|
| Dipyridamole | 1 | 2001 | 3 | 0.010 |
Why?
|
| Cardiovascular Agents | 1 | 2001 | 18 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 2001 | 77 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 2004 | 534 | 0.010 |
Why?
|
| Rheology | 1 | 1995 | 35 | 0.010 |
Why?
|